
China Isotope & Radiation Corporation
1763.HKHKSEHealthcareMedical - Devices
Latest quote
HK$17.00
+HK$0.34 · +2.04%
1763.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteChina Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Junqi Zhang
- Listed since
- Jul 6, 2018
- Employees
- 3,578
Market position
Day range
Current HK$17.00
52-week range
Current HK$17.00
- Open
- HK$16.66
- Previous close
- HK$16.66
- Volume
- 4.6K
- 0.04× average
- Average volume
- 114.69K
- Average daily volume
- Market cap
- 5.44B HKD
- Beta
- 0.48
- Market reference 1
- 50-day average
- HK$17.2944
- -1.70% below average
- 200-day average
- HK$19.7254
- -13.82% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 5.94B CNY
- P/E (TTM)
- 14.58×
- P/B (TTM)
- 0.89×
- P/S (TTM)
- 0.67×
- EV / EBITDA
- 5.08×
- Earnings yield
- 5.50%
- Free cash flow yield
- -0.83%
- Dividend yield
- 2.05%
Profitability & efficiency
- Gross margin
- 50.31%
- Operating margin
- 13.09%
- Net margin
- 4.56%
- Return on equity
- 6.10%
- Return on assets
- 2.03%
- Return on invested capital
- 5.34%
Financial health
- Debt / equity
- 0.52×
- Current ratio
- 1.76×
- Altman Z-score
- 2.23
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7B CNY | 7.57B CNY | 6.63B CNY | 6.15B CNY | 5.14B CNY |
| Cost of goods sold | 3.48B CNY | 3.89B CNY | 3.15B CNY | 2.63B CNY | 1.9B CNY |
| Gross profit | 3.52B CNY | 3.68B CNY | 3.48B CNY | 3.51B CNY | 3.24B CNY |
| Research and development | 294.1M CNY | 300.29M CNY | 306.05M CNY | 300.51M CNY | 196.21M CNY |
| Selling, general, and administrative | 2.33B CNY | 2.33B CNY | 2.4B CNY | 2.36B CNY | 2.32B CNY |
| Operating expenses | 2.61B CNY | 2.6B CNY | 2.54B CNY | 2.61B CNY | 2.46B CNY |
| Interest income | 16.85M CNY | 29.62M CNY | 30.97M CNY | 45.29M CNY | 26.25M CNY |
| Interest expense | 69.18M CNY | 48.42M CNY | 36.14M CNY | 35.34M CNY | 35.8M CNY |
| Depreciation and amortization | 252.98M CNY | 223.23M CNY | 264.35M CNY | 182.76M CNY | 158.58M CNY |
| Operating income | 916.2M CNY | 1.09B CNY | 941.6M CNY | 913.96M CNY | 777.82M CNY |
| Net income | 318.95M CNY | 406.65M CNY | 370.97M CNY | 392.28M CNY | 335.75M CNY |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 0%
- 0 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -55.37%
- 5 comparable reports
- Latest EPS result
- 0.51
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.4254
2025 complete year+95.9% since 2021
2026 partial: HK$0.2604
HK$0.2171
2,021
HK$0.44
2,022
HK$0.4785
2,023
HK$0.4237
2,024
HK$0.4254
2,025
HK$0.2604
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 23, 2026 | HK$0.2604Irregular | Jun 24, 2026 | Aug 17, 2026 |
Dividend | Oct 21, 2025 | HK$0.0884Monthly | Oct 22, 2025 | Dec 31, 2025 |
Dividend | Jun 5, 2025 | HK$0.337Semi-Annual | Jun 6, 2025 | Aug 1, 2025 |
Dividend | Sep 27, 2024 | HK$0.0799Semi-Annual | Sep 30, 2024 | Nov 22, 2024 |
Dividend | Jun 19, 2024 | HK$0.3438Irregular | Jun 20, 2024 | Aug 13, 2024 |
Dividend | Jul 4, 2023 | HK$0.4785Annual | Jul 5, 2023 | Aug 31, 2023 |
Ex-dividend Jun 23, 2026
HK$0.2604
Irregular
Record Jun 24, 2026 · Payment Aug 17, 2026
Ex-dividend Oct 21, 2025
HK$0.0884
Monthly
Record Oct 22, 2025 · Payment Dec 31, 2025
Ex-dividend Jun 5, 2025
HK$0.337
Semi-Annual
Record Jun 6, 2025 · Payment Aug 1, 2025
Ex-dividend Sep 27, 2024
HK$0.0799
Semi-Annual
Record Sep 30, 2024 · Payment Nov 22, 2024
Ex-dividend Jun 19, 2024
HK$0.3438
Irregular
Record Jun 20, 2024 · Payment Aug 13, 2024
Ex-dividend Jul 4, 2023
HK$0.4785
Annual
Record Jul 5, 2023 · Payment Aug 31, 2023
1763.HK peers
ETFs holding 1763.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - Emerging Markets Core Equity 2 ETFDFEM184.44K0.00%9.49B USD0.39%$39.515-1.04%
Dimensional World ex U.S. Core Equity 2 ETFDFAX94.35K0.00%12.57B USD0.28%$37.95-0.55%
Dimensional - Emerging Core Equity Market ETFDFAE57.8K0.00%10B USD0.29%$39.03-1.16%
Avantis Emerging Markets Equity ETFAVEM30.22K—27.89B USD0.33%$93.09-1.22%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE25.92K0.00%638.17M USD0.44%$48.055-1.10%
Avantis Emerging Markets Small Cap Equity ETFAVEE12.17K0.01%122.3M USD0.42%$67.86-0.26%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM- Market value
- 184.44K
- Weight
- 0.00%
- AUM
- 9.49B USD
- Expense ratio
- 0.39%
- Price / 1D
- $39.515-1.04%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- Market value
- 94.35K
- Weight
- 0.00%
- AUM
- 12.57B USD
- Expense ratio
- 0.28%
- Price / 1D
- $37.95-0.55%
Dimensional - Emerging Core Equity Market ETFDFAE- Market value
- 57.8K
- Weight
- 0.00%
- AUM
- 10B USD
- Expense ratio
- 0.29%
- Price / 1D
- $39.03-1.16%
Avantis Emerging Markets Equity ETFAVEM- Market value
- 30.22K
- Weight
- —
- AUM
- 27.89B USD
- Expense ratio
- 0.33%
- Price / 1D
- $93.09-1.22%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE- Market value
- 25.92K
- Weight
- 0.00%
- AUM
- 638.17M USD
- Expense ratio
- 0.44%
- Price / 1D
- $48.055-1.10%
Avantis Emerging Markets Small Cap Equity ETFAVEE- Market value
- 12.17K
- Weight
- 0.01%
- AUM
- 122.3M USD
- Expense ratio
- 0.42%
- Price / 1D
- $67.86-0.26%
Continue in GoAI
Research 1763.HKresearch.disclaimer





